[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Arcutis Biotherapeutics director Neha Krishnamohan received new equity awards, including restricted stock units and stock options. She was granted 5,778 RSUs and 16,667 stock options with a $21.23 exercise price per share. Both the RSUs and options vest 100% on the earlier of June 5, 2026 or immediately before the next annual stockholder meeting, subject to continued service. Following the grant, she holds 27,901 shares of common stock directly, plus the newly granted options for 16,667 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Krishnamohan Neha
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 16,667 | $0.00 | -- |
| Grant/Award | Common Stock | 5,778 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 16,667 shares (Direct, null);
Common Stock — 27,901 shares (Direct, null)
Footnotes (1)
- Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
